Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY

NCT01914484 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT01914484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01914484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY
Lead sponsor
University Health Network, Toronto
Phase
Phase 1/2
Overall status
Completed
Start date
August 1, 2013
Completion date
December 31, 2018
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase chronic myeloid leukemia, blastic phase chronic myeloid leukemia, chronic phase chronic myeloid leukemia, philadelphia positive acute lymphoblastic leukemia, resistant to tyrosine kinase inhibitor therapy